Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

1,546 total articles

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS cut its rating on Swiss property owner Mobimo to sell from neutral, saying the company’s development profits - a key earnings driver - should peak in fiscal 2025 and then decline as high-margin projects complete. The broker raised its 12-month price target to CHF330 from CHF308 after lowering its WACC and modestly raising revenue forecasts, but…

Palladyne AI Wins Air Force Research Laboratory Contract, Stock Jumps on Swarm Integration Work

Palladyne AI Wins Air Force Research Laboratory Contract, Stock Jumps on Swarm Integration Work

Palladyne AI Corp. (NASDAQ:PDYN) saw its shares climb 13% after the Air Force Research Laboratory granted the company a contract named HANGTIME. The program will deploy Palladyne’s SwarmOS™ platform to connect autonomous systems across multiple domains, integrating satellites for the first time and aiming to enable faster, coordinated decision-maki…

Eli Lilly secures up to $1.12 billion agreement with Seamless Therapeutics to pursue gene-editing treatments for hearing loss

Eli Lilly secures up to $1.12 billion agreement with Seamless Therapeutics to pursue gene-editing treatments for hearing loss

Eli Lilly has entered into a collaboration worth as much as $1.12 billion with Germany-based Seamless Therapeutics to develop and commercialize gene-editing therapies aimed at certain forms of hearing loss. The arrangement grants Lilly access to Seamless' proprietary enzyme platform, which engineers programmable recombinases designed to make large,…

UBS Downgrades Intershop to Neutral, Citing Limited Upside After Rally

UBS Downgrades Intershop to Neutral, Citing Limited Upside After Rally

UBS moved Intershop Holding AG (SIX:ISN) from a 'buy' to a 'neutral' rating while increasing its 12-month price target to CHF170. The brokerage says the stock's strong run has restored its valuation to historical norms, leaving scant upside from recent levels. UBS also trimmed revenue and adjusted EPS forecasts for fiscal 2025-27 and highlighted ti…

Eikon Therapeutics Seeks $908.2 Million Valuation in U.S. IPO

Eikon Therapeutics Seeks $908.2 Million Valuation in U.S. IPO

On Jan. 28, Eikon Therapeutics filed to pursue a U.S. initial public offering that would value the company at as much as $908.2 million and raise up to $317.7 million by selling 17.65 million shares at $16 to $18 apiece. The Millbrae, California-based drug developer is advancing a cancer pipeline led by EIK1001, being evaluated in combination with …

AT&T Lays Infrastructure Bets, Sees 2026 Profit Above Street Estimates

AT&T Lays Infrastructure Bets, Sees 2026 Profit Above Street Estimates

AT&T said it expects 2026 adjusted earnings per share to exceed analyst forecasts, attributing the upbeat outlook to planned network investments including the acquisition of Lumen’s consumer fiber assets and EchoStar’s spectrum licenses. The company reported healthy fiber and wireless additions in the fourth quarter and will consolidate 5G and fibe…

Stellantis Deepens Price Cuts in France to Drive Volume Recovery

Stellantis Deepens Price Cuts in France to Drive Volume Recovery

Stellantis said it will step up price reductions on new cars in France, accelerating a program that began in late 2025. The move, announced by the head of Stellantis France, aims to rebuild vehicle sales volumes in the company's largest European market, with discounts already applied to several small car models.

Wells Fargo Wealth Unit Ends Relationship with Proxy Adviser ISS

Wells Fargo Wealth Unit Ends Relationship with Proxy Adviser ISS

Wells Fargo's wealth and investment management division has cut ties with the proxy advisory firm Institutional Shareholder Services (ISS) and will shift to making voting decisions on shareholder proposals using a newly developed in-house process. The move follows similar recent changes among large asset managers and comes amid intensified scrutiny…

Eikon Therapeutics Seeks Up to $908.2 Million Valuation in Planned U.S. IPO

Eikon Therapeutics Seeks Up to $908.2 Million Valuation in Planned U.S. IPO

Eikon Therapeutics has filed for a U.S. initial public offering that would value the company at as much as $908.2 million. The Millbrae, California-based drug developer plans to sell 17.65 million shares at $16 to $18 apiece, aiming to raise up to $317.7 million and list on the Nasdaq under the symbol EIKN as the biotech IPO pipeline gains momentum…